Clearpoint Neuro, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
MAK Capital Fund LP, MAK Capital One LLC, and Michael A. Kaufman have jointly filed a Schedule 13G/A, reporting beneficial ownership of 2,375,861 shares, representing 7.8% of ClearPoint Neuro, Inc.'s common stock.
NASDAQ
SCHEDULE: ClearPoint Neuro: Ownership Update Filed
ClearPoint Neuro, Inc. has filed an amendment to its Schedule 13G, detailing updated beneficial ownership information as of June 30, 2026.
NASDAQ
MAK Capital Fund LP and associated entities have filed an amended Schedule 13G reporting a 6.3% beneficial ownership stake in ClearPoint Neuro, Inc.
NASDAQ
Michael Bigger and associated investment entities have filed a Schedule 13G reporting a 7.54% beneficial ownership stake in ClearPoint Neuro, Inc.
NASDAQ
The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in ClearPoint Neuro Inc. due to an internal organizational realignment.
NASDAQ
MAK Capital Fund LP, MAK Capital One L.L.C., and Michael A. Kaufman have jointly reported a 6.1% beneficial ownership stake in ClearPoint Neuro, Inc.
NASDAQ
Michael Bigger and affiliated entities disclose a combined 7.8% beneficial ownership in ClearPoint Neuro, Inc. through a Schedule 13G Amendment.
NASDAQ
Investment funds Bigger Capital and District 2, along with Michael Bigger, disclose increased passive beneficial ownership in ClearPoint Neuro, Inc., with Michael Bigger now holding 7.6%.
NASDAQ
Bigger Capital Fund LP, District 2 Capital Fund LP, and Michael Bigger have disclosed their beneficial ownership in ClearPoint Neuro, Inc., with Michael Bigger holding a 7.7% stake.
NASDAQ
The Vanguard Group has reported a passive beneficial ownership of 5.27% of ClearPoint Neuro Inc.'s common stock, holding 1,475,120 shares as of June 30, 2025.
NASDAQ
BlackRock, Inc. has reported a 5.6% beneficial ownership stake in ClearPoint Neuro, Inc., holding over 1.58 million shares of common stock.
NASDAQ
SCHEDULE 13G/A: Key Investors Update Significant Stakes in ClearPoint Neuro, Michael Bigger's Aggregate Ownership Reaches 7.5%
An amended Schedule 13G filing reveals updated beneficial ownership stakes in ClearPoint Neuro, Inc. by Bigger Capital, District 2 Capital, and related entities, with Michael Bigger's aggregate ownership reaching 7.5%.
NASDAQ
An investment group led by Michael Bigger has disclosed a 7.4% beneficial ownership stake in ClearPoint Neuro, Inc. through an amended Schedule 13G filing.